FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4376870995> ?p ?o ?g. }

• W4376870995 endingPage "2941" @default.
• W4376870995 startingPage "2927" @default.
• W4376870995 abstract "The unique physiology of tumors limits the efficacy of chemotherapeutics. In efforts to improve the effectiveness of the existing chemotherapy drugs, nanomedicine emerged as a new hope but proved inadequate due to the transport barriers present within the tumor tissues, which limits the potential of nanomedicine. Dense collagen networks in fibrotic tissues contribute to hindering the penetration of molecular- or nano-scale medicine through tumor interstitium. In the present study, human serum albumin (HSA)-based nanoparticles (NPs) were developed for gemcitabine (GEM) and losartan (LST), which could offer secreted protein acids rich in cysteine (SPARC) and enhanced permeability and retention effect (EPR)-mediated drug accumulation in tumors. Also, the tumor microenvironment (TME) modulation approach using LST was coupled to investigate the impact on antitumor efficacy. GEM-HSA NPs and LST-HSA NPs were prepared by the desolvation-cross-linking method and characterized for size, potential, morphology, drug loading, drug–polymer interactions, and hemocompatibility. For investigating the efficacy of prepared NPs, cytotoxicity and mechanisms of cell death were elucidated in vitro by using various assays. Intracellular uptake studies of prepared HSA NPs indicated their uptake and cytoplasmic localization. Furthermore, in vivo studies demonstrated significantly improved anticancer efficacy of GEM-HSA NPs in combination with LST pretreatment. Extended LST treatment further improved the anticancer potential. It was shown that the improved efficacy of the nanomedicine was correlated with the reduced thrombospondin-1 (TSP-1) and collagen level in tumor tissue upon LST pretreatment. Moreover, this approach exhibited augmented nanomedicine accumulation in the tumor, and hematological, biochemical, and tissue histology indicated the safety profile of this combination regimen. Concisely, the undertaken study demonstrated the potential of the triple targeting (SPARC, EPR, TME modulation) approach for augmented efficacy of chemotherapeutics." @default.
• W4376870995 created "2023-05-18" @default.
• W4376870995 creator A5045287452 @default.
• W4376870995 creator A5052031486 @default.
• W4376870995 creator A5052412003 @default.
• W4376870995 creator A5061562879 @default.
• W4376870995 creator A5075840661 @default.
• W4376870995 creator A5077632147 @default.
• W4376870995 creator A5084451037 @default.
• W4376870995 creator A5085389581 @default.
• W4376870995 date "2023-05-17" @default.
• W4376870995 modified "2023-10-18" @default.
• W4376870995 title "Antifibrotic Agent Mediated Tumor Microenvironment Modulation and Improved Nanomedicine Delivery in Solid Tumor" @default.
• W4376870995 cites W1846575105 @default.
• W4376870995 cites W1967513691 @default.
• W4376870995 cites W1967921904 @default.
• W4376870995 cites W1976835184 @default.
• W4376870995 cites W2066411725 @default.
• W4376870995 cites W2080521855 @default.
• W4376870995 cites W2098054841 @default.
• W4376870995 cites W2162651519 @default.
• W4376870995 cites W2167798860 @default.
• W4376870995 cites W2312126744 @default.
• W4376870995 cites W2398626875 @default.
• W4376870995 cites W2471044175 @default.
• W4376870995 cites W2480913527 @default.
• W4376870995 cites W2518611253 @default.
• W4376870995 cites W2772138051 @default.
• W4376870995 cites W2776171184 @default.
• W4376870995 cites W2783056471 @default.
• W4376870995 cites W2807410315 @default.
• W4376870995 cites W2906909370 @default.
• W4376870995 cites W2910703034 @default.
• W4376870995 cites W2923143394 @default.
• W4376870995 cites W2954998262 @default.
• W4376870995 cites W2966953072 @default.
• W4376870995 cites W3004060585 @default.
• W4376870995 cites W3036448116 @default.
• W4376870995 cites W3045539123 @default.
• W4376870995 cites W3092528792 @default.
• W4376870995 cites W3138372428 @default.
• W4376870995 cites W3197990073 @default.
• W4376870995 cites W4224647474 @default.
• W4376870995 cites W805036767 @default.
• W4376870995 doi "https://doi.org/10.1021/acs.molpharmaceut.2c01081" @default.
• W4376870995 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37194684" @default.
• W4376870995 hasPublicationYear "2023" @default.
• W4376870995 type Work @default.
• W4376870995 citedByCount "0" @default.
• W4376870995 crossrefType "journal-article" @default.
• W4376870995 hasAuthorship W4376870995A5045287452 @default.
• W4376870995 hasAuthorship W4376870995A5052031486 @default.
• W4376870995 hasAuthorship W4376870995A5052412003 @default.
• W4376870995 hasAuthorship W4376870995A5061562879 @default.
• W4376870995 hasAuthorship W4376870995A5075840661 @default.
• W4376870995 hasAuthorship W4376870995A5077632147 @default.
• W4376870995 hasAuthorship W4376870995A5084451037 @default.
• W4376870995 hasAuthorship W4376870995A5085389581 @default.
• W4376870995 hasConcept C13245373 @default.
• W4376870995 hasConcept C15083742 @default.
• W4376870995 hasConcept C150903083 @default.
• W4376870995 hasConcept C155672457 @default.
• W4376870995 hasConcept C171250308 @default.
• W4376870995 hasConcept C178790620 @default.
• W4376870995 hasConcept C185592680 @default.
• W4376870995 hasConcept C192562407 @default.
• W4376870995 hasConcept C207001950 @default.
• W4376870995 hasConcept C2776107976 @default.
• W4376870995 hasConcept C2778597219 @default.
• W4376870995 hasConcept C2779820397 @default.
• W4376870995 hasConcept C2780035454 @default.
• W4376870995 hasConcept C3020616263 @default.
• W4376870995 hasConcept C502942594 @default.
• W4376870995 hasConcept C55493867 @default.
• W4376870995 hasConcept C71924100 @default.
• W4376870995 hasConcept C86803240 @default.
• W4376870995 hasConcept C98274493 @default.
• W4376870995 hasConceptScore W4376870995C13245373 @default.
• W4376870995 hasConceptScore W4376870995C15083742 @default.
• W4376870995 hasConceptScore W4376870995C150903083 @default.
• W4376870995 hasConceptScore W4376870995C155672457 @default.
• W4376870995 hasConceptScore W4376870995C171250308 @default.
• W4376870995 hasConceptScore W4376870995C178790620 @default.
• W4376870995 hasConceptScore W4376870995C185592680 @default.
• W4376870995 hasConceptScore W4376870995C192562407 @default.
• W4376870995 hasConceptScore W4376870995C207001950 @default.
• W4376870995 hasConceptScore W4376870995C2776107976 @default.
• W4376870995 hasConceptScore W4376870995C2778597219 @default.
• W4376870995 hasConceptScore W4376870995C2779820397 @default.
• W4376870995 hasConceptScore W4376870995C2780035454 @default.
• W4376870995 hasConceptScore W4376870995C3020616263 @default.
• W4376870995 hasConceptScore W4376870995C502942594 @default.
• W4376870995 hasConceptScore W4376870995C55493867 @default.
• W4376870995 hasConceptScore W4376870995C71924100 @default.
• W4376870995 hasConceptScore W4376870995C86803240 @default.
• W4376870995 hasConceptScore W4376870995C98274493 @default.
• W4376870995 hasFunder F4320320721 @default.
• W4376870995 hasFunder F4320320767 @default.

• next